PDUFA Date
09/2025
Patent Cliff
Adalimumab
Phase III Readout
Q4 2025
BLA Submission
Ustekinumab
Biosimilar Launch
Denosumab
IND Filing
MOA: PD-L1
The formulary decisions your
competitors make next quarter — visible now.
Formulary parses FDA filings, patent cliffs, and pipeline catalogs into actionable drug-launch timelines — before the street prices them in. Built for hospital pharmacy directors, managed-care pharmacists, and biotech BD leads.
Every morning, the FDA publishes
hundreds of filings.
NDAs, BLAs, ANDAs, sNDAs, patent certifications, interchangeability designations — a continuous flood of regulatory signal that takes institutional teams days to parse. Most formulary decisions are made on data that's already weeks stale.
Without Formulary
You're reading all of this manually
Ustekinumab Biosimilar Switch Window: Action Required Before Q2 P&T Cycle
FORMULARY ACTION
Initiate P&T dossier for automatic substitution protocol. CVS Caremark precedent: 97% fill rate shift within 90 days of formulary preference change.
With Formulary — one brief, one decision, zero noise
What you see depends
on your clearance level.
Free tier surfaces enough to confirm the problem exists. Pro tier gives you the decision before the meeting starts.
No credit card. Institutional email required.
14-day full Pro access · Downgrade to Free anytime
After trial: Free tier available indefinitely · Pro from $349/month per institution · Enterprise pricing available
The advantage measured
in days, not opinions.
0
Biosimilars tracked in real-time
$0B
Patent cliff revenue mapped
~0/yr
Average new drug approvals indexed
0%
Prescription shift after formulary preference (CVS precedent)
"We caught the Wezlana interchangeability designation 11 days before our PBM sent the formulary preference notice. That head start let us draft the P&T dossier before the meeting was even scheduled."
Dr. Rachel Kim, PharmD
Director of Pharmacy, Northfield Health System
"The patent cliff timeline for Ozempic and Xarelto alone justified the subscription cost for our entire BD team. We had competitive intelligence on semaglutide generics six weeks before our therapeutic review."
Marcus Webb
VP Business Development, Arctus Biosciences
"Building formulary dossiers used to take my team three days per drug. The AMCP-formatted templates pre-populated with FDA data cut that to four hours. We reviewed 14 biosimilar switches last quarter alone."
Sandra Okonkwo, PharmD, MBA
Managed Care Pharmacy Director, Meridian Health Plan
Patent Cliff 2025–2026:
The $14.8B Cardiovascular Window
Entresto LOE July 2025 · Xarelto 2026 cliff · Ozempic generic pathway · Formulary positioning strategy for each transition. First 3 pages visible. Full 22-page dossier gated.
Institutional email required · No credit card
See what's coming
before the street does.
14 days of full Pro access. Every PDUFA date, every biosimilar switch window, every patent cliff — parsed, prioritized, and delivered to your inbox. Downgrade to Free anytime. No friction.
Institutional email required · HIPAA-compliant infrastructure · SOC 2 Type II